Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects, the company said on Wednes...

Intermittent shortages of diabetes drug Ozempic in the European Union that are expected to continue into the final quarter of 2024 because of strong demand will not affect all member states, the Da...

VANCOUVER, British Columbia, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) is pleased to advise that the Company's Executive Co-...

Eli Lilly and Novo Nordisk compete in a handful of different markets. Novo Nordisk is scaling up its output and upgrading its medicines a bit more slowly.

Wegovy and Ozempic are based on the same molecule called semaglutide. An investigation into the side effects of semaglutide was just published.

A recent study claims that Ozempic is linked with a higher risk of suicidal thoughts than other drugs. However, other studies have reached the opposite conclusion.

Novo Nordisk's Pharmatech unit will build a 1.5 billion Danish crowns ($220.83 million) plant in Denmark to meet significantly higher demand for the production of medicines to fight chronic disease...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.

One of Novo Nordisk's medicines could be helpful for treating Alzheimer's disease. A lot of questions need answering before it'll make any new revenue.

Novo Nordisk A/S investors recently endured a rare bear market after the stock topped out in June 2024. Novo Nordisk faces heightened competitive risks from arch-rival Eli Lilly, as seen in Eli Lil...

Novo Nordisk's sharp price drop following its Q2 2024 results is attributed particularly to slowing sales growth of Wegovy, calling for a closer look at the hugely popular treatment's numbers. A co...

Bagsværd, Denmark, 9 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated per...

Novo Nordisk A/S (NVO) Q2 2024 Earnings Conference Call August 7, 2024 7:00 AM ET Company Participants Jacob Martin Wiborg Rode - Head of Investor Relations Lars Fruergaard Jørgensen - Chief Execut...

Novo Nordisk CEO Lars Fruergaard Jørgensen discusses the pharmaceutical company's second-quarter earnings.